Drugs / Pemtrexed
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05267366 Background | Feb 2022 → Feb 2024 | — | Qingdao Central Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pemtrexed | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05267366 ↗ |
| Route | Intravenous | “Pemtrexed 500mg/m2 iv, d1” NCT05267366 ↗ |